Page 50 - Drug Class Review
P. 50
Final Report Update 1 Drug Effectiveness Review Project
compared to another. Subgroup analyses and indirect
evidence from placebo controlled trials provide evidence
for some AD drugs.
One subgroup analysis reported greater benefit for
rivastigmine in patients older than 75 years. Indirect
comparison of evidence from one donepezil trial conducted
in nursing home residents to trials conducted in younger
populations suggests no apparent difference in efficacy or
adverse events.
Subgroup analyses of pooled data from four donepezil
trials suggest no differences in efficacy or adverse events
by sex or race.
No evidence addressed patients with comorbid Parkinson’s
disease.
Four studies provide general evidence of the efficacy of
donepezil, galantamine, rivastigmine, and memantine in
populations with comorbid vascular dementia. Only one
study stratified patients by vascular risk factors; larger
treatment differences between rivastigmine and placebo
were found for patients with vascular risk factors compared
to patients without vascular risk factors.
No study compared outcomes among subgroups of
patients taking a ChEI or memantine concurrently with
another drug to patients not concurrently taking the same
medication.
Alzheimer's Drugs Page 50 of 205
